Aclarion's Leadership Expansion Signals Focused Push in Eastern U.S.
On December 2, 2025, Aclarion, Inc. announced a pivotal hire: Jason Brosniak, a proven commercial leader with over 20 years in the MedTech space, will now serve as the Commercial Director for the Eastern U.S. This appointment is strategically timed to accelerate the adoption and market expansion of the company’s flagship technology, Nociscan, particularly as physician interest and payer engagement grow in the region.
Brosniak’s Experience Sets Stage for Strong Market Penetration
Brosniak’s background is steeped in successful market launches and the commercialization of breakthrough technologies across spine, orthopedics, and pain management. His resume includes high-impact roles at Relievant Medsystems (acquired by Boston Scientific), Kyphon (acquired by Medtronic), and Intrinsic Therapeutics. These credentials underscore why Aclarion believes he is uniquely positioned to help scale Nociscan and deepen relationships with providers and payers.
| Name | Title | Relevant Experience | Key Responsibility |
|---|---|---|---|
| Jason Brosniak | Commercial Director, Eastern U.S. | 20+ years in MedTech Launched products at Relievant Medsystems, Kyphon, Intrinsic Therapeutics |
Drive adoption of Nociscan and grow payer engagement in Eastern U.S. |
Nociscan Platform Targets Precision in Chronic Back Pain Diagnosis
Nociscan stands out as the first evidence-supported SaaS solution designed to help physicians objectively distinguish between painful and nonpainful lumbar discs. By using proprietary signal processing and augmented intelligence (AI) algorithms on magnetic resonance spectroscopy (MRS) data, Nociscan quantifies chemical biomarkers linked to disc pain. This enables data-driven insights that enhance diagnostic clarity for physicians—a crucial factor given the 266 million people globally who suffer from chronic low back pain.
Strategic Hires Point to Broader Market Ambitions
The timing of Brosniak’s appointment comes as Aclarion builds momentum in payer engagement and increases the volume of real-world evidence trials and a major national CLARITY randomized controlled trial. This follows a similar move in the UK, where Dan Isherwood was recently named Commercial Director, highlighting Aclarion’s goal of expanding Nociscan’s reach both nationally and internationally.
Key Takeaways: Why This Move Matters for Providers and Investors
Aclarion’s choice to bring in a commercially seasoned executive with a history of establishing new market categories suggests an aggressive push for greater adoption and payer support in a critical geography. The continued real-world and clinical evidence backing Nociscan—and the clear drive for expansion—suggest Aclarion is making notable strides in its mission to offer more precise and actionable care for chronic back pain.
While this move signals strategic growth, prospective partners and investors will be watching closely to see if increased adoption in the Eastern U.S. can convert into meaningful revenue and broader payer reimbursement. As real-world evidence continues to accumulate and commercial infrastructure strengthens, the market will soon find out if this expansion can live up to its ambitious goals.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI